Home › Compare › COGNY vs ABBV
COGNY yields 4.85% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, COGNY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of COGNY + ABBV for your $10,000?
Cogna Educação S.A. operates as a private educational organization in Brazil and internationally. The company operates through three segments: In-Class Higher Education, Distance Learning Higher Education, and Basic Education. It offers in-class and distance-learning higher education, and undergraduate and graduate courses; publishes, sells, and distributes textbooks, support materials, and workbooks with educational, literary, and informative content and teaching systems; and educational solutions for professional and higher education, and other supplementary activities, such as developing education technology with management and other education services. The company also provides K-12 education, pre-college preparatory, language courses for children and teenagers; management of child, primary, and secondary education activities; technical and preparatory courses for civil service examinations and Brazilian Bar Association; advises on and/or facilitates direct and indirect student loans; and develops software for adaptive teaching and academic management optimization. Its services include primary, secondary, and postsecondary education services with on-campus undergraduate and graduate programs, and distance learning, as well as graduate programs; preparatory courses under the brand LFG; and unregulated programs. The company operates 176 college education units in 24 Brazilian states and 132 Brazilian cities; and 1,510 distance-learning graduation centers in various Brazilian states and in the Federal District, as well as operates 54 own K-12 education schools, 125 Red Balloon units, and approximately 5,600 associated schools in Brazil. Cogna Educação S.A. was founded in 1998 and is headquartered in Belo Horizonte, Brazil.
Full COGNY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.